Uveal melanoma (UM) is a genetically and biologically distinct type of melanoma, and once metastatic there is no effective treatment currently available. Eighty percent of UMs harbor mutations in the Ga q family members GNAQ and GNA11. Understanding the effector pathways downstream of these oncoproteins is important to identify opportunities for targeted therapy. We report consistent activation of the protein kinase C (PKC) and MAPK pathways as a consequence of GNAQ or GNA11 mutation. PKC inhibition with AEB071 or AHT956 suppressed PKC and MAPK signalling and induced G1 arrest selectively in melanoma cell lines carrying GNAQ or GNA11 mutations. In contrast, treatment with two different MEK inhibitors, PD0325901 and MEK162, inhibited the proliferation of melanoma cell lines irrespective of their mutation status, indicating that in the context of GNAQ or GNA11 mutation MAPK activation can be attributed to activated PKC. AEB071 significantly slowed the growth of tumors in an allograft model of GNAQ Q209L -transduced melanocytes, but did not induce tumor shrinkage. In vivo and in vitro studies showed that PKC inhibitors alone were unable to induce sustained suppression of MAP-kinase signaling. However, combinations of PKC and MEK inhibition, using either PD0325901or MEK162, led to sustained MAP-kinase pathway inhibition and showed a strong synergistic effect in halting proliferation and in inducing apoptosis in vitro. Furthermore, combining PKC and MEK inhibition was efficacious in vivo, causing marked tumor regression in a UM xenograft model. Our data identify PKC as a rational therapeutic target for melanoma patients with GNAQ or GNA11 mutations and demonstrate that combined MEK and PKC inhibition is synergistic, with superior efficacy compared to treatment with either approach alone.
INTRODUCTION
Uveal melanoma (UM) is a genetically and biologically distinct type of melanoma that arises from choroidal melanocytes, that is, melanocytes of the choroidal plexus, ciliary body and iris of the eye. UM is the most common intraocular malignancy in adults and accounts for about 5% of all melanomas. [1] [2] [3] Currently, there are no effective treatment options for patients with metastatic uveal melanoma, and the median survival for a UM patient after diagnosis with metastasis is less than 6 months. 1, 4 Different from melanomas originating from the skin, UM does not harbor mutations in BRAF, NRAS or KIT, but instead shows mutations in GNAQ or GNA11. Over 80% of uveal melanomas harbor mutations in these genes in a mutually exclusive pattern. [5] [6] [7] The two genes encode closely-related large GTPases of the Gaq family, which are (together with b and g subunits) components of heterotrimeric G proteins that transfer signaling through certain types of G-protein coupled receptors to downstream effector proteins. 8, 9 In the absence of agonist binding to the G-protein coupled receptors, the a subunit is bound to GDP and in an inactive configuration. Agonist binding to the G-protein coupled receptors results in a conformational change of the receptor leading the a subunit to exchange GDP to GTP. The GTP-bound a subunit becomes activated and dissociates from bg subunits to interact with specific effector proteins. The intrinsic GTPase activity determines the half-life of the activated GTP-bound a subunit. GNAQ and GNA11 mutations in melanoma affect codons 209 (approximately 95%) or 183 (5%) and result in complete or partial loss of GTPase activity, respectively, thereby leading to constitutive activation of downstream effector pathways. 10, 11 Downstream effectors of Ga q family members include PLC-b isoforms, which hydrolyze PI(4,5)P2 to release inositol trisphosphate (IP3) and diacylglycerol (DAG) from membrane phospholipids. Both compounds act as second messengers that relay and amplify the signaling to downstream components such as release of calcium (IP3) and activation of DAG-responsive proteins.
It has been shown that mutant GNAQ and GNA11 activate the MAP-kinase pathway. 5, 6 However, the specific nature of the oncogenic signaling that results from constitutively activated GNAQ and GNA11 remains incompletely understood. The canonical signaling pathway downstream of Gaq family members includes activation of protein kinase C (PKC). 9, 12 Both DAG and calcium activate members of the PKC family, which is considered a critical hub in distributing signaling to downstream pathways that regulate differentiation, cell proliferation, apoptosis and angiogenesis. 9, 12, 13, 14 The PKC family consists of at least 10 serine/threonine kinases, which are subdivided into classic, novel and atypical isoforms. 14 The classical PKCs (a, bI, bII and g) are DAG and calcium-dependent enzymes, while the novel PKCs (d, e, y and Z) require only DAG for activation. By contrast, the atypical PKCs (z, i/l) are not responsive to activation by DAG or calcium, but are activated by other lipid-derived second messengers.
PKCs are involved in regulating a variety of cell functions, including differentiation, cell proliferation, apoptosis and angiogenesis. 13, 14 The role of PKC in tumorigenesis was first established when they were identified as the cellular target of phorbol esters. Phorbol esters, most prominently 12-O-tetradecanoylphorbol-13-acetate (TPA), are molecular mimics of DAG, which are more potent and not metabolized rapidly. [15] [16] [17] While aberrant PKC activity and expression have been reported in multiple cancers, 14, 18, 19 no specific genetic alterations leading to constitutive activation of the PKC pathway have been found, and clinical trials with PKC inhibitors in cancer have not shown impressive results. The mechanisms by which PKCs contribute to malignancy, however, are still not clear, in part due to the complexities of PKC.
Previous studies have shown that UM cell lines with GNAQ mutations have an increased sensitivity to PKC inhibition in vitro. 20, 21 However, the relationship between PKC and MAPkinase pathway activation in the setting of GNAQ or GNA11 mutations is not fully resolved. It also is not clear whether inhibition of PKC can be translated into meaningful anti-tumor responses in vivo.
Here we demonstrate that the activation of PKC is a direct consequence of activating mutations in GNAQ and GNA11 and confirm that inhibition of PKC leads to selective growth arrest in UM cell lines with mutations in GNAQ and demonstrate that these findings extend to cell lines with mutant GNA11. We further show that MAP-kinase pathway activation occurs as a consequence of PKC activation and can be partially or temporarily suppressed by PKC inhibitors, slowing tumor growth. However, a significantly improved response can be obtained by combined PKC and MEK inhibition, which synergistically result in sustained growth inhibition and apoptosis in vitro and a markedly enhanced antitumoral response in vivo. We propose combinatorial inhibition of PKC and MAP-kinase signaling as a rational therapeutic approach for treating melanomas with GNAQ or GNA11 mutations.
RESULTS
Oncogenic GNAQ and GNA11 activate PKC and MAPK signaling in both mouse and human melanocytes To explore the role of PKC as a mediator of the oncogenic output downstream of mutant GNAQ or GNA11, we examined PKC signaling in a panel of melanoma cell lines, with or without activating mutations in GNAQ or GNA11. We performed western blots using an antibody against phosphorylated myristolated alanine-rich C kinase substrate (p-MARCKS), a substrate of PKC. [22] [23] [24] [25] All six melanoma cell lines with oncogenic GNAQ or GNA11 mutations (GNA11: UPMD-1; OMM-GN11; GNAQ: Mel270; OMM1.3; 92-1 and Mel202) expressed p-MARCKS levels, whereas three of four UM cell lines without mutations in GNAQ and GNA11 (Mel290, MUM2C and Mel285) showed no expression and the fourth (C918) expressed only trace levels. Two of three cutaneous melanoma cell lines (Sk-Mel-28:BRAF  V600E , MM485:NRAS   Q61L and MM415:NRAS Q61L ) that also had no mutations in GNAQ and GNA11 expressed p-MARCKS (Figure 1a) . We performed the following experiments to determine whether the PKC activation in the UM cell lines with oncogenic GNAQ or GNA11 was a consequence of these mutations. First, we introduced Glu-Glu epitope-tagged GNAQ Q209L or GNA11 Q209L into three different cell types, 293T cells, immortalized mouse (melan-a) and immortalized human melanocytes (IHM), and determined the effects on p-MARCKS compared to control cells expressing either GFP, GluGlu tagged GNAQ wt , Glu-Glu tagged GNA11 wt , BRAF V600E or myctagged NRAS G12V . As shown in Figure 1b , expression of GNAQ Q209L or GNA11 Q209L consistently resulted in increased p-MARCKS levels in all three cell types. By contrast, wild-type GNAQ or GNA11 had weak effects, whereas mutant BRAF or NRAS or the GFP control had no effect on p-MARCKS. We ruled out that these differences were due to variation in the expression levels of the transfection constructs using antibodies against the Glu-Glu tag of GNA11 or GNAQ protein, respectively. As shown in Figure 1b , the expression levels of GNAQ Q209L and GNA11 Q209L were consistently similar or lower compared to the expression levels of the wild-type GNAQ and GNA11 proteins in all three different cell types. To confirm that p-MARCKS induction indeed reflected PKC activation by mutant GNAQ or GNA11, we also used an antibody that detects specific phosphorylation motifs of PKC (Arg/Lys-X-Ser phos -HydArg/Lys, where Hyd represents a hydrophobic residue). This experiment revealed an increase in the phosphorylation level of several proteins in cells transduced with GNAQ Q209L and GNA11 Q209L compared to controls, in a pattern consistent throughout the three cell types (Supplementary Figure 1, arrows) . Mutant BRAF or NRAS also led to the appearance of certain bands, but their pattern was distinct and not consistent between the three cells. Taken together, these experiments indicate consistent activation of PKC in UM cell lines, and that this activation is due to mutations in GNAQ and GNA11.
The experiments in Figure 1b also showed a concomitant increase in pERK and p-p90RSK levels in all three cell lines expressing GNAQ Q209L and GNA11 Q209L , indicative of MAPK pathway activation in response to GNAQ or GNA11 mutation, consistent with prior reports. 5, 6 As expected, BRAF V600E and NRAS G12V also resulted in an increase in pERK and p-p90RSK, but did not affect the levels of p-MARCKS. Similar results were also obtained with melan-a cell lines generated to stably express GFP, GNAQ WT , GNA11
WT , GNAQ Q209L , GNA11 Q209L or BRAF V600E , respectively ( Supplementary Figures 2A and B) . This constellation raised the possibility that in the context of mutant GNAQ and GNA11 the MAP-kinase pathway activation is significantly mediated by PKC activation. To confirm this notion and to further corroborate the role of PKC signaling as an effector of mutant GNAQ or GNA11, we performed a series of experiments in UM cell lines that harbored GNAQ or GNA11 mutations.
GNAQ knockdown suppressed PKC and MAPK signaling in melanoma cells harboring GNAQ activating mutations We knocked down the expression of GNAQ with small interfering RNA (siRNAs) in three different melanoma cells (OMM1.3, 92-1 and Mel202) with GNAQ mutation and found PKC and MAPK signaling to be suppressed 72 h after knockdown. As shown in Figure 1c , knockdown of GNAQ inhibited the expression of pMEK, pERK, pMARCKS and p-(ser) PKC substrate compared to non-target siRNA control in all three cell lines. Similar results were also observed with shRNA-mediated knockdown of GNAQ. 92-1 cells were stably transduced with lentiviruses expressing one of three different GNAQ shRNAs or GFP as a control to determine the effect of GNAQ knockdown. As shown in Supplementary Figure 3 (left panel), shRNA1 and shRNA3, which knocked down GNAQ protein most efficiently, also had the strongest effect in reducing the expression levels of p-MARCKS, pERK and the p-(ser)PKC substrate. In contrast, GNAQ shRNA2, which did not deplete GNAQ protein, had no effect on the levels of pMARCKS, p-ERK and p-(ser)PKC substrate. Similar results were obtained when melan-a cells, stably expressing GNAQ Q209L , were transduced with lentiviruses encoding GNAQ shRNA 1 and GNAQ shRNA3 (Supplementary Figure 3 , right panel).
The PKC inhibitors AEB071 and AHT956 selectively inhibit the growth of GNAQ or GNA11 mutant melanoma cell lines To investigate whether PKC inhibition could inhibit growth in melanoma cell lines with GNAQ or GNA11 mutations, we evaluated the antiproliferative effect of two distinct ATP-competitive PKC inhibitors, AEB071 26, 27 and AHT956. We used two panels of six human melanoma cell lines with and without GNAQ or GNA11 mutations, respectively, and three mouse melan-a cell lines stably expressing GNAQ In contrast to the selective effect of PKC inhibitors on GNAQ/11 mutant melanoma cell lines, the MEK inhibitor PD0325901 inhibited melanoma cell lines independent of mutation status (Supplementary Figure 5 and Figure 2c ). To explore the mechanism of the selective growth-inhibitory effects in response to PKC inhibition, we treated GNAQ mutant UM cell lines with 500 nM AEB071 or 100 nM AHT956 and analyzed the effect on cell proliferation and death. The doses were selected to be above their respective IC 50 values. In the GNAQ-mutant 92-1 and OMM1.3 cells, DNA synthesis was significantly suppressed by AEB071 and AHT956 but was unaffected in the two GNAQ wild-type cells (Supplementary Figure 6A ). This coincided with a G1 arrest in the GNAQ mutant but not wild-type cell lines, as evidenced by an increase in the G1 population and concomitant decrease in the fraction of cells in S phase (Supplementary Figure 6B) . The G1 arrest in the GNAQ-mutant cell lines was accompanied by a decrease of phospho-and total RB, downregulation of cyclinD1 and induction of p27, all supporting G1 cell cycle arrest in response to treatment, whereas the level of these proteins remained unaffected in the GNAQ wild-type cell lines (Supplementary Figure 6C) . By contrast, the cell cycle effects of the MEK inhibitor PD0325901 are independent of the mutation status of GNAQ (Supplementary Figure 6D) .
In melanoma cell lines with GNAQ or GNA11 mutation MAPK activation occurs as a consequence of PKC activation The results above indicate that mutations in GNAQ and GNA11 may result in a selective dependency on PKC activation, which could be of therapeutic relevance to treat cancers with these mutations. To confirm that effects of the compounds reflected an on-target effect, we investigated whether their effects on cell growth were paralleled by corresponding effects on the pathways downstream of oncogenic GNAQ or GNA11 ( Figure 1 ). We performed dose-response studies of two panels of four melanoma
Melan Q209L or GNA11 Q209L compared to wild-type GNAQ and GNA11 induces activation of the PKC pathway read out by p-MARCKS and MAP-kinase pathways read out by p-ERK and p-p90RSK in three different cells: immortalized human embryonic kidney cells (293T), mouse melanocytes (melan-a) and immortalized human melanocytes. In comparison, mutant BRAF and NRAS only activate the MAP-kinase pathway. 293T cells were transfected with the respective plasmids for 24 h, whereas melanocytes were infected with lentiviruses for 48 h. Expression levels of GNAQ and GNA11 were monitored using an antibody detecting the Glu-Glu tag. The NRAS antibody detects both endogenous and the larger myc-tagged NRAS proteins (upper bands). (c) Depletion of GNAQ reduces PKC and MAPK signaling. Western blots of three human uveal melanoma cell lines with GNAQ mutation were transfected with non-targeting siRNAs (NT), siRNAs against GNAQ or mock for 72 h and lysed. Note decreased expression of p-MARCKS, p-ERK, p-MEK and certain bands detected by the p-(ser) PKC substrate motif antibody (arrows) with only siRNAs against GNAQ.
cell lines with and without GNAQ or GNA11 mutation by exposing them to increasing doses (0-1 mM) of AEB071 or AHT956 for 24 h. Both compounds, in a dose-dependent manner, abrogated PKC and MAPK signaling, as determined by suppressed levels of p-MARCKS, p-ERK and p-p90RSK in all four GNAQ/11 mutant lines (Figures 3a and b, top panel) . In contrast, the compounds had no effect on MAPK signaling in the four cell lines without GNAQ/11 mutations, although they reduced p-MARCKS at higher concentrations in two (AEB071) or three (AHT956) of the four cell lines (Figures 3a and b, lower panels) . When we treated two of the GNAQ mutant cells (mel202 and 92-1) with the MEK inhibitor PD0325901, we observed the expected dose-dependent inhibition of MAPK signaling, but no effect on p-MARCKS levels, even at higher concentrations (Figure 3c ). In aggregate, our findings indicate that in melanoma cell lines with GNAQ or GNA11 mutations, MAPK pathway activation occurs downstream of PKC.
AEB071 inhibits GNAQ Q209L -mediated tumor growth in vivo
Our data establish PKC activation by oncogenic GNAQ/11 as a critical effector required for melanoma cell growth in vitro. To determine its effect on GNAQ-mediated cell growth in vivo, we used an allograft model with melan-a cells stably expressing GNAQ Q209L injected subcutaneously into c57BL/6 mice. Melan-a cells were originally derived from c57BL/6 mice and GNAQ Q209L -transduced melan-a cells cause rapidly growing tumors in syngeneic mice with histopathological features recapitulating human melanocytic neoplasms with GNAQ mutations. 5 As shown in Figure 4a , oral treatment of tumor-bearing mice with 120 mg/kg AEB071 three times daily elicited a significant growth retardation (58%: Po0.05) but no tumor regression compared to vehicletreated controls. There was no apparent toxicity or change in body weight in the treatment compared to the control arm (data not shown). At the end of the experiment, tumors were excised 2 h after the last treatment, and tumor cell lysates were examined by western blot. There was a substantial reduction in PKC signaling, as evidenced by a decrease in p-MARCKS (Figure 4b , left panel) and p-(ser) PKC substrate levels ( Figure 4b , right panel) in tumors from the treatment group compared to vehicle-treated controls. By contrast, no substantial reduction of pMEK and pERK levels ( Figure 4b ) or evidence of apoptosis was noted in AEB071-treated tumors (data not shown). These results indicate that AEB071 inhibits PKC signaling in vivo, but that compensatory mechanisms prevent the suppression of the MAP-kinase pathway and that the treatment is not sufficient to completely stop cell proliferation or kill cells.
Incomplete suppression of MAPK signaling after long-term treatment with AEB071 in GNAQ-mutant human melanoma cell lines Incomplete suppression or reactivation of the MAPK pathway under treatment is a well-studied phenomenon in melanomas with BRAF mutations following administration of BRAF inhibitors and can occur by several mechanisms linked to resistance. [28] [29] [30] In order to follow MAPK pathway output under continued treatment with AEB071, we performed a time-course experiment with AEB071 in GNAQ-mutant cell lines. As shown in Figure 5a , treatment of both 92-1 and OMM1.3 cells with 250 nM AEB071 resulted in a sustained inhibition of pMARCKS over the 72 h of the experiment. By contrast, there was no complete extinction of MAPK signaling as indicated by sustained expression of pERK and pMEK. Maximal inhibition was observed at about 24 h, with a subsequent subtle increase starting 48 h after treatment in both cell lines. Similar results were observed at twice the concentration of AEB071 (Figure 5b ).
Combined PKC and MEK inhibition synergistically kills GNAQ/11 mutant melanoma cells by induction of apoptosis Combination of an RAF inhibitor with a MEK inhibitor is a successful strategy to increase pathway inhibition and treatment response in patients with BRAF-mutant melanomas. 31 Considering incomplete suppression of MAPK signaling with PKC inhibition alone, we attempted to improve treatment efficacy and inhibition of MAPK signaling using a combination of PKC and MEK inhibition. We exposed two GNAQ mutants, one GNA11 mutant and two melanoma cell lines without either mutation to combinations of AEB071 and PD0325901 at doses ranging from 0 to 5 mM and 0 to 0.5 mM, respectively, and determined the effect on 0  1000  500  250  100  25  0  1000  500  250  100  25  0  1000  500  250  100  25   0  1000  500  250  100  25  0  1000  500  250  100  25   0  1000  500  250  100  25  0  1000  500  250  100 (Figure 6a ) where growth inhibition relative to non-treated cells is visualized using a color scale. We observed an improved growth inhibition of the combinations in all three melanoma cells with GNAQ/11 mutation (92-1, OMM1.3 and OMM-GN11) compared to treatments with either compound alone. Isobologram analysis 32 ( Figure 6b ) and Combination Index (Supplementary Figure 7) revealed that the effects of AEB071 and PD0325901 were strongly synergistic. By contrast, no improved effect of the combination was seen in melanoma cells without GNAQ/11 mutations (MUM2C and Mel285).
A combination of 250 nM AEB071 and 20 nM PD0325901 inhibited proliferation of 92-1 and OMM1.3 to a greater extent, compared to the individual compounds at these concentrations (Figure 6c ). In 92-1 cells and less pronounced in OMM1.3 cells, a reduction of cell numbers was also observed, indicating that the combination caused cell death (Figure 6c ). As shown in Figure 6d , the combination of AEB071 and PD0325901 resulted in a significant increase in cleaved PARP level, supporting this notion. The combination treatment resulted in near-complete extinction of pMEK and pERK expression in all three melanoma cells with GNAQ or GNA11 mutation, compared to treatment with the individual inhibitors alone. In contrast, the combination did not increase levels of cleaved PARP or reduce pMEK and pERK levels in the three control cell lines without GNAQ and GNA11 mutations. Similar synergistic results were also observed with a combination Figure 8A and B) . Only the combination of AEB071 and MEK162 yielded sustained suppression of pMEK and pERK in UM cell lines with GNAQ or GNA11 mutations (Supplementary Figure 9) . Interestingly, we observed that single-agent treatment with one of two different MEK inhibitors (PD0325901 or MEK162) resulted in the accumulation of pMEK in GNAQ and GNA11 mutant melanoma cells due to relieved negative feedback on the MAPK pathway (Figure 6d and Supplementary Figure 9 ). This observation is comparable and consistent with the findings in BRAF wild-type melanomas treated by MEK inhibitors. 33 However, this increase in pMEK could be suppressed by concomitant administration of AEB071 in the GNAQ and GNA11 mutant cells, whereas it had no effect in cell lines without GNAQ and GNA11 mutations (c918 and mel285) (Figure 6d and Supplementary Figure 9) .
of AEB071 and another MEK inhibitor MEK162 (Supplementary
Taken together, these results suggest that a combination of PKC and MEK inhibition leads to sustained blockade of MAP-kinase signaling and induction of cell death in melanoma cell lines with GNAQ or GNA11 mutations. To determine whether the synergistic effects of combined MEK and PKC inhibition translate into improved in vivo efficacy, we used a mouse xenograft model in which subcutaneous tumors are generated by injecting the GNAQ-mutant human UM cell line 92-1 into nude mice. After 12 days, the tumors had grown to 108-256 mm 3 , and the mice were divided into eight groups. Treatment with AEB071 and MEK162 alone or combination with different doses was initiated for 21 days. As shown in Figure 7 , AEB071 monotherapy resulted in slow growth of tumors compared to vehicle control in a dosagedependent manner. AEB071 monotherapy at the highest dosage (TID at 80 mg/kg) inhibited tumor growth by 82% (Po0.05). By contrast, MEK162 monotherapy administered twice daily at 3.5 mg/kg inhibited tumor growth by about 44% compared to vehicle control. The combination treatment of AEB071 and MEK162 led to a significant reduction of tumor growth compared to monotherapy with either compound in a dose-dependent manner. At higher doses, the combination led to significant (P-values o0.001) tumor shrinkage (12% tumor regression at 40 mg/kg TID of AEB071 and 3.5 mg/kg BID MEK162 and 52% regression at 80 mg/kg TID of AEB071 and 3.5 mg/kg BID MEK162 compared to initial tumor volume before treatment). Those results Media were changed after 24 h and cells were lysed after treatment for 48 h. For 92-1 and OMM1.3 cells, the drug concentrations used were AEB071 250 nM and PD0325901 100 nM. For OMM-GN11, c918, MUM2C, Mel285, the drug concentrations used were AEB071 1000 nM and PD0325901 100 nM.
are consistent with in vitro data ( Figure 6 ), suggesting that the combination of PKC and MEK inhibition has a synergistic effect on melanomas with GNAQ mutation.
DISCUSSION
Our study highlights PKC signaling as a critical oncogenic effector pathway in melanomas with oncogenic GNAQ and GNA11 mutations and as a potential therapeutic target for UM. The importance of PKC is indicated by several lines of evidence: (1) we found a consistent increase in PKC activation across a panel of UM cell lines with GNAQ or GNA11 mutations; (2) depletion of mutant GNAQ in these lines abrogates PKC activation, whereas (3) introduction of mutant GNAQ or GNA11 into human and murine melanocytes activated PKC.
Activation of PKC has been reported in a broad range of cancer types. However, the therapeutic efficacy of PKC inhibitors in the treatment of cancer patients has been disappointing. [34] [35] [36] Our results indicate that melanoma cells with GNAQ or GNA11 mutations are selectively sensitive to PKC inhibition, consistent with the findings from other groups. 20, 21 We show here that these findings extend to melanoma cell lines with GNA11 mutations, but that neither cells do express selective sensitivity to MEK inhibitors, compared to melanoma cell lines without these mutations. Using two different PKC inhibitors across a panel of six different UM cell lines with GNAQ or GNA11 mutations and two melanocyte lines stably expressing GNAQ or GNA11, the inhibitors reduced growth at IC 50 s ranging from 56 to 467 nM for AEB071 and from 4 to 159 nM for AHT956, whereas melanoma cell lines with other mutations, irrespective of whether they were derived from uveal or cutaneous melanoma, were not sensitive. Interestingly, two of the latter cell lines also showed PKC activation as evidenced by expression of phospho-MARCKS (Figure 1 ). This indicates that in contrast to other cell lines GNAQ or GNA11 mutant cell lines are dependent on PKC activation to initiate critical growth pathways. The role of PKC activation in melanocyte proliferation is well established. The synthetic DAG analogue TPA is a potent mitogen for melanocytes, including the melan-a cells used in our study, which were derived from normal epidermal melanoblasts from embryos of C57BL/6 mice. 37 In the absence of TPA, melan-a cells do not proliferate, even when grown in full serum 37 (Supplementary Figure 10) . The precise mechanism of TPA action is not clear, but it has been demonstrated to activate PKC in human melanocytes 38 and mouse melanocytes (Supplementary Figure 11A and B) . In contrast to normal melan-a cells, melan-a cell lines stably expressing GNAQ Q209L or GNA11 Q209L proliferate independently of TPA (Supplementary Figure 10) . The observation that oncogenic GNAQ and GNA11 are able to substitute for addition of TPA to the growth medium further supports the notion that these oncogenes exert parts of their proliferation-promoting effect through activation of PKC.
Our results and published data indicate that MAP-kinase pathway activation is a critical component of oncogenic signaling in the context of mutant GNAQ or GNA11 and occurs downstream of PKC. Prior studies have shown that Ga q Q209L can stimulate MAPK pathway via PLC-DAG-PKC, presumably by PKC-mediated phosphorylation of Raf-1.
39-41 MAP-kinase pathway activation has also been demonstrated via PLC-IP3-Ca2 þ -Pyk2-Src-Ras signaling, 12 and the precise conduit of signaling in the context of mutant GNAQ or GNA11 remains to be determined. In our study with two different PKC inhibitors, PKC inhibition attenuated MAPK phosphorylation in the context of GNAQ or GNA11 mutation, whereas MEK inhibition only blocked MAPK phosphorylation, with no effect on PKC activation in GNAQ or GNA11 mutant cells (Figure 3) . The experiments using the PKC substrate motif antibody revealed that introduction of mutant BRAF or NRAS also results in PKC activation, but with a different spectrum of phosphorylation targets than Ga q Q209L (Supplementary Figure 1) . As BRAF signals predominantly through the MAP-kinase pathway, in melanoma cells with BRAF mutations PKC most likely becomes activated as a consequence of MAP-kinase pathway activation, contrary to the context of mutant GNAQ or GNA11 where the MAP-kinase pathway operates downstream of PKC.
MAP-kinase pathway activation via PKC appears to represent a major proliferative stimulus in the context of GNAQ or GNA11 mutations, as both PKC or MEK inhibition led to G1 arrest with loss of phospho-RB, reduction of cyclin D1 and upregulation of the negative cell cycle regulator p27kip1. The findings are consistent with the effects of MEK inhibition in BRAF mutant melanoma cells. 42 PKC inhibition with either PKC inhibitor alone did not result in cell death in UM cell lines with GNAQ or GNA11 mutations at the doses used in our study. Wu et al. 20 found that AEB071 at high doses (5 mM) induced apoptosis in 92-1, mel202 and omm1.3 UM cell lines, which harbor GNAQ mutations. In the allograft experiment with melan-a cells transduced with GNAQ Q209L , AEB071 slowed tumor growth at the maximally tolerated dose level, but did not result in tumor regression or apoptosis. These findings may have implications for the clinical use of PKC inhibitors for the treatment of patients with UM. A clinical trial with AEB071 is currently underway in patients with UM with GNAQ or GNA11 mutations. While the results of this trial are not yet available, our data indicate that AEB071 monotherapy may primarily slow tumor growth rather than induce significant tumor shrinkage. The finding that the treated tumors in our allograft experiment continued to express pERK while PKC output continued to be suppressed points to additional complexity in the activation of the MAP-kinase pathway in the context of GNAQ or GNA11 mutation. The incomplete pERK suppression was already visible in vitro, where under continuous PKC inhibition the MAP-kinase pathway was only transiently suppressed. The rapid nature of the rebound makes a genetic mechanism less likely, and instead points to relieve of feedback inhibition as a potential mechanism. 43 A similar phenomenon has been observed with the use of BRAF inhibitors in melanoma cells with BRAF mutations, in which the MAP-kinase pathway becomes re-activated after 24 h of treatment. In this setting, the addition of an MEK inhibitor overcomes the rebound and leads to sustained pathway suppression. 44 The intriguing synergy between compounds targeting the same pathway in a seemingly redundant fashion has now been shown to have clinical benefits in patients with BRAF mutant melanomas. 45 These findings motivated us to investigate a combination of PKC inhibition and MEK inhibition, and we also found a strong synergistic effect of the two approaches both in vitro and in vivo ( Figures 6 and 7 and Supplementary Figures 8 and 9 ) associated with nearly full suppression of pMEK and pERK levels in melanomas with GNAQ and GNA11 mutation. Melanomas with activated MAPK signaling mediated by oncogenes such as BRAF 46 and GNAQ/11( Figure 2c and Supplementary Figures 5 and 6D ) were sensitive to MEK inhibition. However, MEK inhibitors inhibit ERK signaling in all cells including normal tissues, resulting in a reduced therapeutic index. 47 The accumulation of pMEK induced by MEK inhibition in GNAQ and GNA11 mutant cells is consistent with the findings in BRAF wild-type melanoma cells 33, 48 and has been explained by the abrogation of negative feedback pathways as a consequence of MEK inhibition. Recent studies show that pMEK accumulation induced by MEK inhibitors indicates the sensitivity of cells to MEK inhibitors, indicating residual MEK activity in the presence of the inhibitor. 48 Using two different MEK inhibitors, we found that pMEK accumulation in response to MEK inhibition can be abrogated by the addition of the PKC inhibitor AEB071 (Figure 6d and Supplementary Figure 9 ) in the GNAQ/11 mutant cells, but not melanoma cell lines without GNAQ/11 mutations. While this could point to a role of PKC in the negative feedback loop, a simpler explanation is that PKC inhibition reduces some of the pathway flux upstream of MEK, coming from mutant GNAQ or GNA11. Although we used both classical allograft and xenograft mouse model to perform in vivo study for convenient and economic purpose, a liver metastatic mouse model is worth exploring in the future. We conclude that in the setting of GNAQ or GNA11 mutation the combined treatment with PKC and MEK inhibitors may improve treatment responses in patients with metastatic UM compared to either of the two compounds alone. The data provided indicate that the combination may allow reducing the doses of the individual compounds, which is expected to improve the tolerability of the drugs.
MATERIALS AND METHODS

Plasmids and reagents
The GNAQ and GNA11 cDNA constructs were obtained from Missouri S&T cDNA Resource Center. They are internally Glu-Glu tagged, with altered residues at positions 171-176 from AYLPTQ(GNAQ) or GYLPTQ (GNA11) to EYMPTE and were cloned into Plenti6 lentiviral vectors (Invitrogen, Grand Island, NY, USA). All constructs were sequenced for confirmation. AEB071,AHT956 and MEK162 were synthesized at Novartis Pharma AG (East Hanover, NJ, USA). PD0325901 was obtained from Chemie Tek (Indianapolis, IN, USA). G06976 was purchased from Calbiochem (La Jolla, CA, USA).
Cell culture and cell line generation
The sources of the melanoma cell lines have been previously described. 49 Melanoma cell lines were maintained in RPMI 1640 with 10% FBS. 293T cells were cultured in DMEM with 10%FBS. . Forty-eight hours after lentivirus infection, cells were selected with blasticidin (10 mg/ ml) for 2 weeks.
Transient transfection, lentiviral transduction and knockdown of GNAQ by siRNA 
Proliferation assays
Cells were plated in triplicate into six-well plates at 5 Â 10 4 cells per well, and the following day were treated with or without the indicated concentrations of AEB071 or AHT956 or PD0325901, with media changes every day for AEB071 and AHT956, every 2 days for PD0325901. Cells were collected by trypsinization and counted in a Vi-Cell cell viability analyzer (Beckman Coulter, Brea, CA, USA) or TC10 Automated Cell Counter ( BioRad, Hercules, CA, USA). IC 50 values were calculated using Prism software (La Jolla, CA, USA).
Cell cycle analysis and BRDU labeling Cells were seeded in six-well plates with 1.5 Â 10 5 cells per well 1 d before treatment with AEB071 or AHT956 for 72 h. Before fixation, cells were incubated with 40 mM BRDU for 4 h and labeled with an anti-BRDU FITC antibody and 7-AAD for cell cycle assays using the FITC BRDU Flow Kit ( BD Pharmingen, San Jose, CA, USA) according to the manufacturer's instructions. Fluorescence-activated cell sorting was carried out to determine cell cycle distribution and the percentage of BRDU-positive cells using a Cell Lab Quanta flow cytometer (Beckman Coulter).
In vivo allograft studies 1 Â 10 6 melan-a cells stably expressing GNAQ Q209L were injected into the flanks of c57/Bl6 mouse and allowed 10-14 days to reach a tumor volume of about 100 mm 3 . Subsequently, the animals received 120 mg/kg AEB071 (n ¼ 9) or vehicle control (n ¼ 9) three times per day for 3 weeks by oral PKC inhibition in cell lines carrying GNAQ or GNA11 mutations X Chen et al gavage. Tumor volume was recorded twice per week. After 3 weeks of treatment, animals were euthanized and tumors were harvested and analyzed by western blotting. All animal experiments were performed in accordance with a protocol approved by the Institutional Animal Care and Use Committee of the Memorial Sloan-Kettering Cancer Center.
Synergy analysis of drug combinations
Cells were plated in triplicate into 96-well tissue culture plates at 1000-3000 cells per well, depending on doubling times. On the next day, mixtures of inhibitors were added to the cells according to the planned dose matrices. Media were changed after 2-day treatment. Cell viability was analyzed 96 h later by using CellTiter 96 Aqueous One solution (Promega Corporation, Madison, MI, USA) according to the manufacturer's instructions. Plates were read in a SpectraMax M2 plate reader (Molecular Devices, Sunnyvale, CA, USA).
Isobologram analysis was performed using the Chalice Multi-target Discover Software (Zalicus, Cambridge, MA, USA). The CompuSyn software (ComboSyn, Paramus, NJ, USA) was used to calculate the CI value to indicate additive or synergistic effects. 50 A CI of 1 was interpreted as additive and CIo1 as synergistic.
In vivo drug combination analysis
The 92-1 UM cells were harvested during exponential growth and resuspended in cold PBS with 50% Matrigel (BD Biosciences, San Jose, CA, USA). Each 9-week-old female athymic nude mouse (Crl:NU(Ncr)-Foxn1nu, Charles River, Hollister, CA, USA) was inoculated subcutaneously in the right flank with 5 Â 10 6 cells (0.2 ml of cell suspension). Tumors were calipered in two dimensions to monitor growth as their mean volume approached the desired 100-150 mm 3 range. Tumor size, in mm 3 , was calculated from: tumor volume ¼ (w 2 Â l)/2, where w is the width and l the ¼ length, in mm, of the tumor. Twelve days after tumor cell implantation, on Day 1 of the study, animals with individual tumor volumes of 108-256 mm 3 were sorted into eight groups (n ¼ 10/group) with group mean tumor volumes of 130-140 mm 3 . Subsequently, the animals received different treatment for 21 days by oral gavage. Tumor volumes were measured twice per week till the end of the study. The animal program at DRS-NC is accredited by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) International, which assures compliance with accepted standards for the care and use of laboratory animals.
